ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA  98034

 

Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

 

Close Window

A World Leader in Therapeutics and

Diagnostics Targeting Amyloid Diseases

 

ProteoTech's intellectual property estate covering new proprietary technologies currently consists of over 173 patents in its portfolio, including 88 issued patents in the US and Internationally. This extensive portfolio covers technologies relating to:

 

  • Alzheimer's disease
  • Parkinson's disease
  • Other amyloid diseases such as Systemic AA Amyloidosis, and Type 2 Diabetes

 

This extensive landscape of intellectual property covers a wide range of applications including:

 

  • Therapeutics (compositions of matter, new chemical entities, synthetic routes and methods of use)
  • Diagnostics for Alzheimer's and Parkinson's disease
  • Platform in vitro and animal model screening technologies for the development of new compounds
News

November 11, 2008
ProteoTech to Present at Rodman & Renshaw's 10th Annual Healthcare Conference

 

August 07, 2008
ProteoTech's Exebryl-1® Enters Human Clinical Trials for the Treatment of Alzheimer's Disease

 

July 29, 2008
Exebryl-1® Phase I Human Clinical Trial for Alzheimer's disease commences

 

July 25, 2008
ProteoTech to present at International Alzheimer's Conference—Chicago, IL.

 

May 28, 2008
ProteoTech receives clearance from FDA to proceed with Phase I Human Clinical Trials for Exebryl-1®

 

May 15, 2008
ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

 

April 28, 2008
ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease